Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

We have observed 4 EP applications Birgit Otzen Petersen has served for within the last five+ years. (We consider all applications which have an EP A1 or A2 publication dated after October 12, 2013). Please note, that we only count EP applications, in which the name of the patent attorney is explicitly mentioned as representative. These EP applications are:

EP13720714

HUMAN CD30 LIGAND ANTIGEN BINDING PROTEINS

IPC classification:
C07K 16/28
Applicant:
Amgen Inc
Applicant:
Novo Nordisk A/S
Agent:
EIP Europe LLP
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
EXAMINATION IN PROGRESS
EP14708903

GROWTH HORMONE COMPOUNDS

IPC classification:
C12N 5/10, C12P 21/02, C07K 19/00
Applicant:
Novo Nordisk Health Care AG
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
EXAMINATION IN PROGRESS
EP14715022

GROWTH HORMONE COMPOUND FORMULATION

IPC classification:
A61K 47/26, A61K 47/18, A61K 47/10, A61K 47/48, A61K 38/27
Applicant:
Novo Nordisk Health Care AG
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
EXAMINATION REQUESTED
EP14818938

METHOD FOR THIOETHER CONJUGATION OF PROTEINS

IPC classification:
C07K 14/00, A61K 47/48
Applicant:
Novo Nordisk Health Care AG
Agent:
Birgit Otzen Petersen, Novo Nordisk A/S
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature